On Monday, Relmada Therapeutics Inc (NASDAQ: RLMD) was -9.96%% drop from the session before settling in for the closing price of $0.68. A 52-week range for RLMD has been $0.24 – $4.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 0.68%. When this article was written, the company’s average yearly earnings per share was at 27.17%. With a float of $26.73 million, this company’s outstanding shares have now reached $33.19 million.
Considering the fact that the conglomerate employs 17 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Relmada Therapeutics Inc (RLMD) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Relmada Therapeutics Inc stocks. The insider ownership of Relmada Therapeutics Inc is 19.46%, while institutional ownership is 25.04%. The most recent insider transaction that took place on May 16 ’25, was worth 86,060. In this transaction Chief Operating Officer of this company bought 200,000 shares at a rate of $0.43, taking the stock ownership to the 412,295 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Financial Officer bought 90,000 for $0.49, making the entire transaction worth $43,686. This insider now owns 228,335 shares in total.
Relmada Therapeutics Inc (RLMD) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 27.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.28% during the next five years compared to 0.68% growth over the previous five years of trading.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
You can see what Relmada Therapeutics Inc (RLMD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -0.99 in one year’s time.
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Compared to the last year’s volume of 1.46 million, its volume of 0.3 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 10.55%.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 56.03%, which indicates a significant increase from 3.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.27% in the past 14 days, which was lower than the 171.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5382, while its 200-day Moving Average is $1.3216. Nevertheless, the first resistance level for the watch stands at $0.6533 in the near term. At $0.6967, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.7233. If the price goes on to break the first support level at $0.5833, it is likely to go to the next support level at $0.5567. Now, if the price goes above the second support level, the third support stands at $0.5133.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
There are 33,192K outstanding shares of the company, which has a market capitalization of 20.28 million. As of now, sales total 0 K while income totals -79,980 K. Its latest quarter income was 0 K while its last quarter net income were -17,560 K.
